INDICATIONS

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease.. READ MORE

    • For US healthcare professionals

    Broader Coverage, Better Access with Repatha®

    are covered for Repatha® across insurance types1,*

    The Process For Getting Insurance Approval for Repatha® Has Improved

    For Commercial Patients, Where a Prior Authorization is Required:

    Eighty five percentage Icon

    of plans
    Do Not Require
    additional
    documentation1,†

    Seventy nine percentage Icon

    of plans
    Do Not Require
    an ezetimibe
    step through1,†,‡

    Seventy eight percentage Icon

    of plans
    Do Not Require
    multiple-statin
    step through1,†

    For Commercially Insured Patients, ~3 out of 10 have no Prior Authorization requirement1,†

    For Medicare Patients, Where a Prior Authorization is Required:

    Eighty one percentage Icon

    of plans
    Do Not Require
    additional
    documentation1,†

    Eighty one percentage Icon

    of plans
    Do Not Require
    an ezetimibe
    step through1,†,‡

    Seventy nine percentage Icon

    of plans
    Do Not Require
    multiple-statin
    step through1,†

    Repatha® May Cost Your Patients Less Than You Think

    Across All Payor Types MORE THAN 81% PRESCRIPTIONS for Repatha® Patients Cost $50 or less2,**

    COMMERCIAL

    per month with the Repatha® Co-Pay card§ for eligible commercially insured patients.

    MEDICARE

    for ~73% of Repatha® prescriptions2,**,††

    MEDICAID

    for ~99% of Repatha® prescriptions2,**

    Encourage Patients to Sign up for Amgen® SupportPlus

    Personalized support that you and your patients can count on across Amgen® therapies.
    Learn more here

    *Covered includes Covered, Disadvantaged, and Not Covered as defined by Managed Markets Insights and Technology (MMIT) data. Number of insured lives provided is obtained from MMIT for health plans in the United States as of August 2024.

    †Based on MMIT data for health plans in the United States as of August 2024. This information is subject to change without notice. For the most up-to-date and complete information regarding coverage of Repatha®, please contact the relevant payer directly.

    ‡Defined as ezetimibe being optional, in which step therapy requirements can be satisfied with either a statin or ezetimibe, or no step requirement, or as one statin, including generic statin, atorvastatin, rosuvastatin, simvastatin or 1 of ezetimibe/statin, specific to plan requirements. Plan’s details are subject to change without notice, please refer to payer requirements directly.

    §Eligibility criteria and program maximums apply. Please see full Terms and Conditions at Repatha.com/copaytcs.

    **Based on IQVIA claims data from 1/1/2023 to 12/31/2023 using the respective Medicare or Medicaid data.

    ††The patient’s out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit the patient is currently in.

    PA=prior authorization

    References: 1. Data on file, Amgen; [1]; 2024. 2. Data on file, Amgen; [2]; 2024.

    Important Safety Information

    Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

    Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

    Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

    From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

    Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

    Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

    Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

    Indications

    Repatha® is indicated:

    • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease
    • as an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C

    Please see full Prescribing Information.

    Important Safety Information

    Back To Top